| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
|
Medicine details |
|
| Medicine name | ustekinumab (Stelara®) |
| Formulation | solution for injection |
| Reference number | 324 |
| Indication | Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/08/2008 |
| NICE guidance | TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |